ICON PLC

Chart & Performance

D1W1MN

P/E

27.98

P/S

2.11

EPS

7.42

Div Yield, %

0.00%

Shrs. gr., 5y

8.61%

Rev. gr., 5y

25.62%

Revenues

8.12b

+4.89%

Net income

612m

+21.18%

CFO

1.16b

+106.11%

Earnings

Feb 19, 2025

Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.

URL

https://www.iconplc.com/

IPO date

May 15, 1998

Employees

41,160

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	8,120,176 4.89%	7,741,386 41.24%	5,480,826 95.93%
Cost of revenue	5,719,949	5,527,045	3,972,612
Unusual Expense (Income)
NOPBT	2,400,227	2,214,341	1,508,214
NOPBT Margin	29.56%	28.60%	27.52%
Operating Taxes	11,749	59,411	41,334
Tax Rate	0.49%	2.68%	2.74%
NOPAT	2,388,478	2,154,930	1,466,880
Net income	612,335 21.18%	505,304 229.87%	153,185 -53.27%
Dividends
Dividend yield
Proceeds from repurchase of equity	50,957	(64,156)	117,736
BB yield	-0.22%	0.40%	-0.56%
Debt
Debt current	146,564	55,150	55,150
Long-term debt	3,954,495	4,862,325	5,700,128
Deferred revenue			735
Other long-term liabilities	232,652	277,448	213,970
Net debt	3,674,199	4,594,363	4,976,388
Cash flow
Cash from operating activities	1,161,027	563,315	829,142
CAPEX	(140,692)	(142,160)	(93,750)
Cash from investing activities	(226,653)	(145,867)	(6,024,235)
Cash from financing activities	(844,043)	(864,173)	5,114,728
FCF	2,334,972	1,875,148	1,294,134
Balance
Cash	380,056	290,481	753,925
Long term investments	46,804	32,631	24,965
Excess cash	20,851		504,849
Stockholders' equity	2,298,074	1,656,495	1,331,783
Invested Capital	13,390,868	13,519,459	13,313,045
ROIC	17.75%	16.06%	19.68%
ROCE	16.77%	15.26%	10.12%
EV
Common stock shares outstanding	82,718	82,468	68,068
Price	283.07 45.72%	194.25 -37.28%	309.70 58.84%
Market cap	23,414,882 46.17%	16,019,480 -24.01%	21,080,756 102.91%
EV	27,089,081	20,613,843	26,057,144
EBITDA	2,986,177	2,783,854	1,823,201
EV/EBITDA	9.07	7.40	14.29
Interest	336,699	229,731	182,423
Interest/NOPBT	14.03%	10.37%	12.10%